https://www.selleckchem.com/products/pki587.html
0% at less than or equal to 3 m/s to 83.3% at greater than 5 m/s. TAPAC reduced mean blood loss by 36.3% in comparison with a historical control cohort ( p 0.001), without increasing the number of thrombotic or thromboembolic events during the hospital stay. With ascending v max , there was an increase in perioperative blood loss in the historical cohort ( p 0.001), which was not evident in the TAPAC cohort ( p = 0.23. The prevalence of aVWS in CHD seems to be higher than assumed and leads to significantly higher perioperativ
Like
Comment
Share
